- Gilenya (fingolimod): Drug Safety Communication - Safety Review of a Reported Death After the First Dose
- Hydromorphone Hydrochloride Injection 1 MG/ML, (C-II) 1 ML Fill In 2.5 ML Carpuject: Recall - May Contain More Than the Intended Fill Volume
- Revlimid (lenalidomide): Ongoing Safety Review - Increased Risk of Developing New Malignancies
- Certain Compounded Drugs from Franck's: FDA Issues Second Warning to Physicians
- Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs: Drug Safety Communication - Drug Interactions
- X-Rock: Recall - Undeclared Drug Ingredient
- Roche Diagnostics Operations Elecsys Troponin I and Elecsys Troponin I STAT Immunoassays: Recall – Doctors may receive a falsely low result
- Brilliant Blue G Compounded by Franck's: Recall of Unapproved Drug - Ongoing Investigation of Fungal Endophthalmitis Cases
- Aliskiren-containing Medications: Drug Safety Comunication - New Warning and Contraindication
- Other‐Sonic Generic Ultrasound Transmission Gel: Safety Communication - Risk of Bacterial Contamination
- Morphine Sulfate Injection USP, 4 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject by Hospira, Inc: Recall - May Contain More Than Intended Fill Volume
- Birth Control Pills Containing Drospirenone: Label Change-Products may be associated with a higher risk for blood clots
- Thoratec Corporation, HeartMate II Left Ventricular Assist System (LVAS): Class 1 Recall- Outflow Graft May Kink or Deform
- Altuzan (bevacizumab): Counterfeit Product - Contains no Active Ingredient
- Celexa (citalopram hydrobromide) - Drug Safety Communication: Revised Recommendations, Potential Risk of Abnormal Heart Rhythms
FDA Medwatch
